These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35368622)

  • 21. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia.
    Siegler JE; Klein P; Yaghi S; Vigilante N; Abdalkader M; Coutinho JM; Abdul Khalek F; Nguyen TN
    Stroke; 2021 Aug; 52(9):3045-3053. PubMed ID: 34304601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK
    Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.
    Cari L; Alhosseini MN; Fiore P; Pierno S; Pacor S; Bergamo A; Sava G; Nocentini G
    J Autoimmun; 2021 Dec; 125():102742. PubMed ID: 34710832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers.
    Petito E; Colonna E; Falcinelli E; Mezzasoma AM; Cesari E; Giglio E; Fiordi T; Almerigogna F; Villa A; Gresele P
    Br J Haematol; 2022 Jul; 198(2):257-266. PubMed ID: 35577507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.
    Kristyanto H; Slaets L; Braams E; Scheys I; Heesbeen R; Cárdenas V; Shukarev G; Scheper G; Sadoff J; Lühn K; Schuitemaker H; Struyf F; Hendriks J
    J Thromb Haemost; 2024 Dec; 22(12):3532-3541. PubMed ID: 39278600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
    Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
    JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population.
    Iheanacho CO; Eze UIH; Adida EA
    Bull Natl Res Cent; 2021; 45(1):150. PubMed ID: 34456555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story.
    Tsilingiris D; Vallianou NG; Karampela I; Dalamaga M
    Metabol Open; 2021 Sep; 11():100101. PubMed ID: 34179744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
    Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity of Humoral Immune Responses, Adverse Reactions, and Post-Vaccination Morbidity after Adenovirus Vector-Based and mRNA Anti-COVID-19 Vaccines.
    Voulgaridi I; Sarrou S; Dadouli A; Peristeri AM; Nasika A; Onoufriadis I; Kyritsi MA; Anagnostopoulos L; Theodoridou A; Avakian I; Pappa D; Konstantinou AK; Papadamou G; Mouchtouri VA; Petinaki E; Speletas M; Hadjichristodoulou C
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination.
    Aid M; Stephenson KE; Collier AY; Nkolola JP; Michael JV; McKenzie SE; Barouch DH
    Nat Commun; 2023 Oct; 14(1):6703. PubMed ID: 37872311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites.
    Abbattista M; Martinelli I; Peyvandi F
    J Thromb Haemost; 2021 Oct; 19(10):2554-2558. PubMed ID: 34375510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis.
    Kim AY; Woo W; Yon DK; Lee SW; Yang JW; Kim JH; Park S; Koyanagi A; Kim MS; Lee S; Shin JI; Smith L
    Int J Infect Dis; 2022 Jun; 119():130-139. PubMed ID: 35339716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
    Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney Transplantation from a Deceased Donor with COVID-19 Ad26.COV2-S Vaccine-Induced Thrombotic Thrombocytopenia.
    Neretljak I; Jurenec F; Smojver H; Jurekovic Z
    Am J Case Rep; 2023 Apr; 24():e938730. PubMed ID: 37087559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination.
    Ivanko I; Ćelap I; Margetić S; Marijančević D; Josipović J; Gaćina P
    Thromb Res; 2023 Aug; 228():137-144. PubMed ID: 37329722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.